The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal’s Zegfrovy (sunvozertinib) to treat a ...

Early commercialisation is one of the most demanding stages in bringing a therapy to market, and the challenges are only ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).

A WHO report emphasises the serious global impact of antimicrobial resistance, which exacerbates the substantial burden of ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

Camera fatigue: being on camera means always being on show. This can be distracting for some individuals who are constantly ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

The European Commission (EC) has granted conditional approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab) to treat a ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be approved in combination with ...